News
AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the new drug.
The Company History page lists out the major events in chronological order for AstraZeneca Pharma India Ltd. Company History - AstraZeneca Pharma India Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback